We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Ubiquitous nuclear and nucleolar expression in essentially all cells except in glial- and stroma cells.
IMMUNOHISTOCHEMISTRY DATA RELIABILITY
Data reliability descriptioni
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Several cases of melanomas and colorectal cancers along with few liver, testis, urothelial, prostatic, ovarian, cervical, renal and head and neck cancers showed moderate nucleolar positivity. Remaining cancer tissues were in general weakly stained or negative.
Moderate nuclear and sometimes cytoplasmic positivity was observed in most cancers. Skin, urothelial, stomach and pancreatic cancers were mainly weak or negative.
A majority of cancer tissues showed moderate to strong nucleolar and/or cytoplasmic staining.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. [provided by RefSeq, Jul 2008]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
MYC-001
MYC-002
MYC-003
MYC-004
MYC-005
MYC-006
MYC-201
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
A0A087WUS5 [Direct mapping] Myc proto-oncogene protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations COSMIC Translocations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0000320 [re-entry into mitotic cell cycle] GO:0001541 [ovarian follicle development] GO:0001701 [in utero embryonic development] GO:0002082 [regulation of oxidative phosphorylation] GO:0003677 [DNA binding] GO:0003690 [double-stranded DNA binding] GO:0003700 [transcription factor activity, sequence-specific DNA binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005730 [nucleolus] GO:0005737 [cytoplasm] GO:0006006 [glucose metabolic process] GO:0006351 [transcription, DNA-templated] GO:0006352 [DNA-templated transcription, initiation] GO:0006355 [regulation of transcription, DNA-templated] GO:0006366 [transcription from RNA polymerase II promoter] GO:0006848 [pyruvate transport] GO:0006865 [amino acid transport] GO:0007007 [inner mitochondrial membrane organization] GO:0007346 [regulation of mitotic cell cycle] GO:0008134 [transcription factor binding] GO:0008283 [cell proliferation] GO:0008284 [positive regulation of cell proliferation] GO:0009611 [response to wounding] GO:0009812 [flavonoid metabolic process] GO:0010629 [negative regulation of gene expression] GO:0010918 [positive regulation of mitochondrial membrane potential] GO:0014911 [positive regulation of smooth muscle cell migration] GO:0019087 [transformation of host cell by virus] GO:0021854 [hypothalamus development] GO:0030728 [ovulation] GO:0032355 [response to estradiol] GO:0032869 [cellular response to insulin stimulus] GO:0035690 [cellular response to drug] GO:0036120 [cellular response to platelet-derived growth factor stimulus] GO:0043388 [positive regulation of DNA binding] GO:0043565 [sequence-specific DNA binding] GO:0044330 [canonical Wnt signaling pathway involved in positive regulation of wound healing] GO:0044344 [cellular response to fibroblast growth factor stimulus] GO:0044752 [response to human chorionic gonadotropin] GO:0045023 [G0 to G1 transition] GO:0045471 [response to ethanol] GO:0045787 [positive regulation of cell cycle] GO:0045821 [positive regulation of glycolytic process] GO:0045893 [positive regulation of transcription, DNA-templated] GO:0045944 [positive regulation of transcription from RNA polymerase II promoter] GO:0046325 [negative regulation of glucose import] GO:0046722 [lactic acid secretion] GO:0046982 [protein heterodimerization activity] GO:0046983 [protein dimerization activity] GO:0048146 [positive regulation of fibroblast proliferation] GO:0048661 [positive regulation of smooth muscle cell proliferation] GO:0060252 [positive regulation of glial cell proliferation] GO:0060548 [negative regulation of cell death] GO:0071300 [cellular response to retinoic acid] GO:0071322 [cellular response to carbohydrate stimulus] GO:0071346 [cellular response to interferon-gamma] GO:0071347 [cellular response to interleukin-1] GO:0071364 [cellular response to epidermal growth factor stimulus] GO:0071378 [cellular response to growth hormone stimulus] GO:0071391 [cellular response to estrogen stimulus] GO:0071394 [cellular response to testosterone stimulus] GO:0071407 [cellular response to organic cyclic compound] GO:0071409 [cellular response to cycloheximide] GO:0071464 [cellular response to hydrostatic pressure] GO:0071966 [fungal-type cell wall polysaccharide metabolic process] GO:0097421 [liver regeneration] GO:1901857 [positive regulation of cellular respiration] GO:1903841 [cellular response to arsenite(3-)] GO:1903862 [positive regulation of oxidative phosphorylation] GO:1904385 [cellular response to angiotensin] GO:1904586 [cellular response to putrescine] GO:1904620 [cellular response to dimethyl sulfoxide] GO:1904628 [cellular response to phorbol 13-acetate 12-myristate] GO:1990646 [cellular response to prolactin] GO:1990858 [cellular response to lectin] GO:1990859 [cellular response to endothelin] GO:2001171 [positive regulation of ATP biosynthetic process]
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations COSMIC Translocations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0003700 [transcription factor activity, sequence-specific DNA binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0006355 [regulation of transcription, DNA-templated]
H0YBG3 [Direct mapping] Myc proto-oncogene protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations COSMIC Translocations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0003700 [transcription factor activity, sequence-specific DNA binding] GO:0005634 [nucleus] GO:0006355 [regulation of transcription, DNA-templated]
H0YBT0 [Direct mapping] Myc proto-oncogene protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations COSMIC Translocations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0003700 [transcription factor activity, sequence-specific DNA binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0006355 [regulation of transcription, DNA-templated] GO:0046983 [protein dimerization activity]
E5RGD7 [Direct mapping] Myc proto-oncogene protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations COSMIC Translocations Protein evidence (Ezkurdia et al 2014)
Predicted intracellular proteins Transcription factors Basic domains Cancer-related genes Candidate cancer biomarkers COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations COSMIC Translocations Disease related genes Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000082 [G1/S transition of mitotic cell cycle] GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0000165 [MAPK cascade] GO:0000978 [RNA polymerase II core promoter proximal region sequence-specific DNA binding] GO:0001077 [transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding] GO:0001658 [branching involved in ureteric bud morphogenesis] GO:0002053 [positive regulation of mesenchymal cell proliferation] GO:0003677 [DNA binding] GO:0003700 [transcription factor activity, sequence-specific DNA binding] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005730 [nucleolus] GO:0005829 [cytosol] GO:0006112 [energy reserve metabolic process] GO:0006338 [chromatin remodeling] GO:0006351 [transcription, DNA-templated] GO:0006355 [regulation of transcription, DNA-templated] GO:0006357 [regulation of transcription from RNA polymerase II promoter] GO:0006366 [transcription from RNA polymerase II promoter] GO:0006879 [cellular iron ion homeostasis] GO:0006974 [cellular response to DNA damage stimulus] GO:0007050 [cell cycle arrest] GO:0007219 [Notch signaling pathway] GO:0008134 [transcription factor binding] GO:0008284 [positive regulation of cell proliferation] GO:0010332 [response to gamma radiation] GO:0010468 [regulation of gene expression] GO:0015671 [oxygen transport] GO:0016579 [protein deubiquitination] GO:0032204 [regulation of telomere maintenance] GO:0032403 [protein complex binding] GO:0032873 [negative regulation of stress-activated MAPK cascade] GO:0034644 [cellular response to UV] GO:0035690 [cellular response to drug] GO:0042493 [response to drug] GO:0043066 [negative regulation of apoptotic process] GO:0043234 [protein complex] GO:0043280 [positive regulation of cysteine-type endopeptidase activity involved in apoptotic process] GO:0044346 [fibroblast apoptotic process] GO:0045656 [negative regulation of monocyte differentiation] GO:0045893 [positive regulation of transcription, DNA-templated] GO:0045944 [positive regulation of transcription from RNA polymerase II promoter] GO:0046983 [protein dimerization activity] GO:0048146 [positive regulation of fibroblast proliferation] GO:0048147 [negative regulation of fibroblast proliferation] GO:0050679 [positive regulation of epithelial cell proliferation] GO:0051276 [chromosome organization] GO:0051782 [negative regulation of cell division] GO:0051973 [positive regulation of telomerase activity] GO:0060070 [canonical Wnt signaling pathway] GO:0070491 [repressing transcription factor binding] GO:0070848 [response to growth factor] GO:0070888 [E-box binding] GO:0090096 [positive regulation of metanephric cap mesenchymal cell proliferation] GO:1904837 [beta-catenin-TCF complex assembly] GO:2000573 [positive regulation of DNA biosynthetic process] GO:2001022 [positive regulation of response to DNA damage stimulus]
A0A087WUS5 [Direct mapping] Myc proto-oncogene protein
Show all
Predicted intracellular proteins Cancer-related genes COSMIC somatic mutations in cancer genes COSMIC Amplifications COSMIC Somatic Mutations COSMIC Translocations Protein evidence (Ezkurdia et al 2014)
Show all
GO:0003700 [transcription factor activity, sequence-specific DNA binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0006355 [regulation of transcription, DNA-templated] GO:0046983 [protein dimerization activity]
The Human Protein Atlas project is funded
MENU
